What is the recommended treatment for squamous cell carcinoma of the anal opening?

Treatment of Squamous Cell Carcinoma of the Anal Opening

Concurrent chemoradiation therapy (CRT) with mitomycin-C (MMC) plus a fluoropyrimidine (5-fluorouracil or capecitabine) is the standard definitive treatment for stage I-III anal squamous cell carcinoma, allowing most patients to avoid abdominoperineal resection and preserve anal sphincter function. 1

Primary Treatment Approach

Standard Chemoradiation Regimen

The preferred treatment consists of concurrent chemoradiation with the following radiosensitizing chemotherapy options 1:

First-line option:

• MMC (10 mg/m² [max 20 mg] on day 1 and day 29, OR 12 mg/m² [max 20 mg] on day 1 only) + 5-FU continuous infusion 1
• MMC + capecitabine (825 mg/m² twice daily on radiation days) is an acceptable oral alternative to 5-FU 1

Alternative option for specific populations:

• Cisplatin (60 mg/m² on days 1 and 29) + 5-FU 1

Patient Selection for Chemotherapy Regimens

For immunosuppressed patients (including HIV-positive):

• Cisplatin + 5-FU is the preferable regimen due to myelosuppression risk with MMC 1

Contraindications to cisplatin:

• Renal dysfunction, significant neuropathy, or hearing loss 1
• Carboplatin substitution is NOT recommended as there is no evidence supporting this approach 1

MMC dosing considerations:

• One cycle of MMC (day 1 only) is a reasonable option given excellent results and reduced hematologic toxicity 1
• The second dose on day 29 increases toxicity and should be used with caution 1
• No established criteria exist for selecting one versus two doses, but immunosuppressed patients or those with HIV may benefit from single-dose MMC due to higher leukopenia risk 1

What NOT to Do

Induction chemotherapy before CRT is NOT recommended:

• Multiple trials including ACCORD 16 and RTOG 98-11 showed no benefit to induction chemotherapy with 5-FU/cisplatin 1
• No improvement in colostomy-free survival, overall survival, or local control 1
• Exception: Retrospective data suggests potential benefit for T4 tumors specifically, but this is not standard practice 1

Adjuvant/maintenance chemotherapy after CRT is NOT recommended:

• The ACT II trial showed no significant difference in 3-year progression-free survival with maintenance chemotherapy 1

Cetuximab-based regimens should be AVOIDED:

• Phase II trials (E3205, AMC045, ACCORD 16) demonstrated substantially increased toxicity 1
• Grade 4 toxicity rates of 26-32% with treatment-related deaths 1
• ACCORD 16 was terminated prematurely due to extremely high serious adverse event rates 1

Special Populations and Situations

Very Early Stage Disease (T1N0)

For highly selected T1N0 tumors 2:

• Local excision alone may be considered for very small tumors (mean size ~11 mm) 2
• However, 82.8% of T1N0 patients in the French ANABASE cohort received radiation therapy, reflecting clinical uncertainty 2
• 24-month recurrence-free survival was similar between local excision (92.2%) and RT (94.6%), though numbers were small 2

Patients Unable to Tolerate Standard Therapy

For elderly or frail patients who cannot tolerate MMC 1:

• Weekly cisplatin + daily 5-FU during radiation is used by some NCCN panel members 1
• Capecitabine + radiation or radiation alone are potential strategies, though data are limited 1
• Geriatric assessment to guide management is critical 1

Salvage Treatment

Abdominoperineal resection is reserved for:

• Persistent disease after CRT 3, 4
• Recurrent disease beyond 26 weeks 4
• This results in permanent colostomy but may be curative 3, 4

Critical Counseling Points

Before initiating radiation therapy 1:

• Counsel on infertility risks
• Offer sperm banking or oocyte/egg/ovarian tissue banking as appropriate

Long-term toxicity discussion 1:

• Sexual dysfunction and anorectal dysfunction can significantly affect quality of life
• Preventive and supportive care strategies should be discussed upfront

Emerging Therapies (Not Yet Standard)

Immunotherapy is under investigation:

• Phase III trial of nivolumab (PD-1 inhibitor) following CRT for high-risk disease has completed enrollment (NCT03233711), results pending 1
• Immunotherapy shows promise in metastatic disease but is not yet standard for localized anal cancer 5

Common Pitfalls to Avoid

• Do not delay diagnosis: Anal cancer is often misdiagnosed or diagnosis is delayed 3
• Do not use carboplatin as cisplatin substitute: No evidence supports this 1
• Do not add cetuximab: Increases toxicity without proven benefit 1
• Do not routinely use induction or maintenance chemotherapy: No survival benefit demonstrated 1
• Distinguish anal canal from anal margin tumors: This has implications for staging and treatment approach 3